Page last updated: 2024-08-21

adamantane and Psoriasis

adamantane has been researched along with Psoriasis in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	3 (42.86)	24.3611
2020's	3 (42.86)	2.80

Authors

Authors	Studies
Guo, L; Jiang, X; Wang, L; Zhang, L	1
Georgiou, S; Plachouri, KM	1
Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R	1
Cardwell, LA; Cline, A; Feldman, SR	1
Akinlade, B; Ball, G; Catlin, M; Krueger, JG; Papp, K; Pariser, D; Wierz, G; Zeiher, B	1
Warren, RB; Yiu, ZZ	1
Avery, M; Bhagavathula, N; Chittiboyina, A; Ellis, CN; Kurtz, TW; Nerusu, KC; Pershadsingh, HA; Reddy, M; Varani, J	1

Reviews

5 review(s) available for adamantane and Psoriasis

Article	Year
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis. Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:11 Topics: Adamantane; Azetidines; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Janus Kinases; Network Meta-Analysis; Niacinamide; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Sulfonamides; Treatment Outcome	2022
JAK inhibitors in chronic plaque psoriasis: What is known so far. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:2 Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles	2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the rheumatic diseases, 2021, Volume: 80, Issue:1 Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles	2021
Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18 Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide	2017
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. American journal of clinical dermatology, 2016, Volume: 17, Issue:3 Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles	2016

Trials

1 trial(s) available for adamantane and Psoriasis

Article	Year
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. The British journal of dermatology, 2015, Volume: 173, Issue:3 Topics: Adamantane; Biopsy; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Niacinamide; Psoriasis; Skin; Treatment Outcome	2015

Article

Year

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

The British journal of dermatology, 2015, Volume: 173, Issue:3

Topics: Adamantane; Biopsy; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Niacinamide; Psoriasis; Skin; Treatment Outcome

2015

Other Studies

1 other study(ies) available for adamantane and Psoriasis

Article	Year
BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application. The Journal of pharmacology and experimental therapeutics, 2005, Volume: 315, Issue:3 Topics: Adamantane; Administration, Topical; Animals; Epidermis; Humans; Hyperplasia; Mice; Mice, SCID; Molecular Structure; Psoriasis; Skin Transplantation; Thiazolidinediones; Time Factors; Transplantation, Heterologous	2005

Article

Year

BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application.

The Journal of pharmacology and experimental therapeutics, 2005, Volume: 315, Issue:3

Topics: Adamantane; Administration, Topical; Animals; Epidermis; Humans; Hyperplasia; Mice; Mice, SCID; Molecular Structure; Psoriasis; Skin Transplantation; Thiazolidinediones; Time Factors; Transplantation, Heterologous

2005